Third time lucky for Novartis?

Posted 12 June 2025 AM

Despite consecutive court losses in its defence of Entresto, Novartis hopes to head back to the bench to once again battle Pharmacor over a key patent on the multimillion-dollar heart drug.

In March the company lost a Federal Court appeal against an original decision disallowing a patent term extension (PTE) on the product, which is a combination of sacubitril and valsartan. That decision would have left Pharmacor unencumbered in marketing its genericised and PBS listed version of the combination, Valtresto, and sister brand Sacubitril/Valsartan Pharmacor.

To see the whole article, please login